Skip to Content

Minoxidil (Topical)

Pronunciation

Pronunciation

(mi NOKS i dil)

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Foam, External:

Rogaine Mens Extra Strength: 5% (60 g [DSC]) [contains sd alcohol 40b]

Solution, External:

Hair Regrowth Treatment Men: 5% (60 mL) [contains alcohol, usp, propylene glycol]

Minoxidil for Men: 2% (60 mL)

Minoxidil for Men: 2% (60 mL) [contains alcohol, usp]

Minoxidil for Men: 5% (60 mL, 120 mL) [contains alcohol, usp, propylene glycol, water, purified]

Generic: 5% (60 mL [DSC])

Brand Names: U.S.

  • Hair Regrowth Treatment Men [OTC]
  • Minoxidil for Men [OTC]
  • Rogaine Mens Extra Strength [OTC] [DSC]

Pharmacologic Category

  • Topical Skin Product

Pharmacology

Stimulation of hair growth is secondary to vasodilation, increased cutaneous blood flow, and stimulation of resting hair follicles.

Use: Labeled Indications

Alopecia: Treatment of alopecia androgenetica of the scalp

Contraindications

OTC labeling: When used for self-medication, do not use if your degree of hair loss is different than that shown on the product labeling; if you have no family history of hair loss; if your hair loss is sudden and/or patchy; if your hair loss is associated with childbirth; if you do not know the reason for your hair loss; in pediatric patients <18 years; if your scalp is red, inflamed, infected, irritated, or painful; or you use other medicines on the scalp. Do not use products on women that are labeled for use on men.

Dosing: Adult

Alopecia: Topical: Note: Continuous therapy for 4 months may be necessary for hair growth.

Females:

Foam, aerosol 5%: Apply 1/2 capful once daily

Solution 2%: Apply 1 mL twice daily

Males:

Foam, aerosol 5%: Apply 1/2 capful twice daily

Solution 2% or 5%: Apply 1 mL twice daily

Dosing: Renal Impairment

There are no dosage adjustments provided in the manufacturer’s labeling

Dosing: Hepatic Impairment

There are no dosage adjustments provided in the manufacturer’s labeling

Administration

Topical: For topical administration on the scalp only; do not use on other parts of the body. Apply directly to the hair- thinning areas of scalp; massage into scalp with fingers; wash hands after application. Refer to manufacturer’s labeling for additional administration instructions.

Foam: May melt upon contact with warm fingers; rinse fingers in cold water and thoroughly dry prior to use

Storage

Foam: Store at 20°C to 25°C (68°F to 77°F). Do not puncture or incinerate container. Do not expose to heat or store at temperatures >49°C (120°F).

Solution: Store at 20°C to 25°C (68°F to 77°F).

Drug Interactions

CycloSPORINE (Systemic): May enhance the adverse/toxic effect of Minoxidil (Topical). Specifically, hypertrichosis risk may be increased. Monitor therapy

Adverse Reactions

Dermatologic: Local erythema (6%), pruritus (6%)

Warnings/Precautions

Concerns related to adverse effects:

• Hair color changes: Changes in hair color and/or texture may occur.

Disease-related concerns:

• Heart disease: Due to potential systemic absorption with subsequent fluid/electrolyte changes, a careful risk to benefit assessment should be performed in patients with heart disease before the use of topical minoxidil.

Dosage form specific issues:

• Flammable: Formulations are flammable; avoid fire, flame, or smoking immediately following application.

Other warnings/precautions:

• Appropriate use: For topical use only on the scalp; do not apply to other parts of the body. Avoid contact with eyes, mouth, nose, or other mucous membranes. Not intended for frontal baldness or receding hairline Continued use is necessary to increase and maintain hair regrowth.

• Self-medication (OTC use): When used for self-medication (OTC), discontinue use and contact your contact health care provider if chest pain, rapid heartbeat, faintness, or dizziness occurs; weight gain (sudden, unexplained) occurs; swelling of the hands or feet occurs; scalp irritation or redness occurs; unwanted facial hair growth occurs; if you do not see hair regrowth 4 to 6 months (product dependent).

Pregnancy Considerations

Adverse events have been observed in some animal reproduction studies following oral administration.

Patient Education

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Patient may experience eye irritation or hair discoloration. Have patient report immediately to prescriber angina, severe dizziness, passing out, tachycardia, excessive weight gain, swelling of arms or legs, or severe skin irritation (HCAHPS).

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.

Hide